All Stories

  1. Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antieme...

    Article • International Journal of Clinical Oncology, September 2024, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  2. Impact of the First Twenty-Four-Hour Area Under the Concentration-Time Curve/Minimum Inhibitory Concentration of Vancomycin on Treatment Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia

    Article • Journal of Clinical Medicine Research, August 2024, Elmer Press, Inc.

    Ph.D. Toshinobu Hayashi

  3. Assessing the ability of the Cancer and Aging Research Group tool to predict chemotherapy toxicity in older Japanese patients: A prospective observational study

    Article • Journal of Geriatric Oncology, July 2024, Elsevier

    Ph.D. Toshinobu Hayashi

  4. Effects of renin-angiotensin system inhibitor and beta-blocker use on mortality in older patients with heart failure with reduced ejection fraction in Japan

    Article • Frontiers in Cardiovascular Medicine, May 2024, Frontiers

    Ph.D. Toshinobu Hayashi

  5. Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity

    Article • Scientific Reports, May 2024, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  6. A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-

    Article • Investigational New Drugs, December 2023, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  7. Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy

    Article • Expert Opinion on Pharmacotherapy, November 2023, Taylor & Francis

    Ph.D. Toshinobu Hayashi

  8. Adrenaline-resistant anaphylactic shock caused by contrast medium in a patient after risperidone overdose: a case report

    Article • Journal of Pharmaceutical Health Care and Sciences, July 2023, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  9. Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer

    Article • European Journal of Clinical Pharmacology, January 2023, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  10. Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy

    Article • Oncology, January 2023, Karger Publishers

    Ph.D. Toshinobu Hayashi

  11. Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy

    Article • Cancer Management and Research, September 2022, Taylor & Francis

    Ph.D. Toshinobu Hayashi

  12. Therapeutic effect of anti-HMGB1 antibody in a mouse model of 4-h middle cerebral artery occlusion: comparison with tissue plasminogen activator

    Article • Neuroreport, April 2022, Wolters Kluwer Health

    Ph.D. Toshinobu Hayashi

  13. Assisted Living and Medication Adherence in Super-aged Patients With Heart Failure in the Japanese Population

    Article • Journal of Cardiovascular Pharmacology, April 2022, Wolters Kluwer Health

    Ph.D. Toshinobu Hayashi

  14. Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthr...

    Article • BMJ Open, March 2022, BMJ

    Ph.D. Toshinobu Hayashi

  15. Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score–matched analysis

    Article • Supportive Care in Cancer, January 2022, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  16. Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk

    Article • BMC Cancer, October 2021, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  17. Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score–matched analysis

    Article • Supportive Care in Cancer, February 2021, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  18. Effects of Recommended Consultation Practice Using Fracture Risk Assessment Tool and Fracture Evaluation Questionnaire for Early Detection of Osteoporosis at Community Pharmacies

    Article • YAKUGAKU ZASSHI, February 2021, Pharmaceutical Society of Japan

    Ph.D. Toshinobu Hayashi

  19. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis

    Article • BMC Cancer, January 2021, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  20. 5HT 3 RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy‐induced nausea and vomiting in colorectal cancer

    Article • Cancer Science, December 2020, Wiley

    Ph.D. Toshinobu Hayashi

  21. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study

    Article • BMC Pharmacology and Toxicology, October 2020, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  22. Effect of lubiprostone on vinca alkaloid–induced constipation in patients with hematological malignancies: a propensity score–matched analysis

    Article • Annals of Hematology, August 2020, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  23. Antithrombin gamma attenuates macrophage/microglial activation and brain damage after transient focal cerebral ischemia in mice

    Article • Life Sciences, July 2020, Elsevier

    Ph.D. Toshinobu Hayashi

  24. Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients

    Article • International Journal of Hematology, March 2020, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  25. Evaluation of the Collaboration between Community Interprofessionals and Pharmacists for Early Detection of Dementia

    Article • YAKUGAKU ZASSHI, December 2019, Pharmaceutical Society of Japan

    Ph.D. Toshinobu Hayashi

  26. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan

    Article • The Oncologist, October 2019, Oxford University Press (OUP)

    Ph.D. Toshinobu Hayashi

  27. Evaluation of Combination Antiemetic Therapy on CINV in Patients With Gynecologic Cancer Receiving TC Chemotherapy

    Article • Anticancer Research, December 2018, International Institute of Anticancer Research

    Ph.D. Toshinobu Hayashi

  28. Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study

    Article • Cancer Management and Research, October 2018, Dove Medical Press

    Ph.D. Toshinobu Hayashi

  29. Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy

    Article • Supportive Care in Cancer, November 2017, Springer Science + Business Media

    Keita Hirai, Ph.D. Toshinobu Hayashi

  30. Involvement of Charcot-Marie-Tooth disease gene mitofusin 2 expression in paclitaxel-induced mechanical allodynia in rats

    Article • Neuroscience Letters, July 2017, Elsevier

    Ph.D. Toshinobu Hayashi

  31. Comprehensive study of risk factors for chemotherapy-induced nausea and vomiting in cancer patients receiving cisplatin-based chemotherapy: A TRIPLE pharmacogenomics study.

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    Keita Hirai, Ph.D. Toshinobu Hayashi

  32. A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting

    Article • Supportive Care in Cancer, March 2017, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  33. P3.05-007 Prospective Evaluation for Combination Antiemetic Therapy on CINV in NSCLC Receiving Carboplatin-Based Chemotherapy of MEC

    Article • Journal of Thoracic Oncology, January 2017, Elsevier

    Ph.D. Toshinobu Hayashi

  34. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study

    Article • Annals of Oncology, August 2016, Elsevier

    Ph.D. Toshinobu Hayashi

  35. Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study

    Article • The Pharmacogenomics Journal, May 2016, Nature

    Keita Hirai, Ph.D. Toshinobu Hayashi

  36. Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era

    Article • International Journal of Hematology, August 2014, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  37. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma

    Article • Japanese Journal of Radiology, July 2012, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  38. Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation

    Article • Supportive Care in Cancer, September 2011, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  39. Vaccination with dendritic cells pulsed with apoptotic cells elicits effective antitumor immunity in murine hepatoma models

    Article • International Journal of Oncology, May 2005, Spandidos Publications

    Ph.D. Toshinobu Hayashi

  40. Diverse efficacy of vaccination therapy using the α-fetoprotein gene against mouse hepatocellular carcinoma

    Article • International Journal of Molecular Medicine, January 2004, Spandidos Publications

    Ph.D. Toshinobu Hayashi